Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital had launched a clinical study, along with the pharmaceutical company Takeda, to evaluate the efficacy and safety of Icatibant as a treatment against COVID-19.
The study has also permitted identify genetic variants that modify the expression of genes in the colon and that are associated with diseases such as colorectal cancer, but also with other organs such as the brain, showing the relationship between the intestine and the brain.
An investigation by the International Center for Numerical Methods in Engineering (CIMNE) and the University of Lleida (UdL), in which IDIBELL and the Hospital de Bellvitge has participated, has developed automated voice markers to identify early affectations of the disease.
To equilibrate the gene expression between XX females and XY males, one of female X chromosomes is inactivated. Researchers from IDIBELL Regenerative Program has discovered that this inactivation is affected in bone marrow aged stem cells.